ReviewCurrent cancer drug targets2026
Advances and Future Prospects of Lipid-Based Nanocarriers in Targeted Cancer Therapy: A Comprehensive Review.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells.Frontiers in drug delivery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTargeted cancer therapy has significantly transformed the field of oncology by improving treatment precision and reducing the occurrence of unintended side effects. Lipid-based nanocarriers have become a viable platform for delivering chemotherapeutic drugs due to their biocompatibility, flexibility, and ability to be functionalised. AIMS AND
objectivesThe objective of this research is to investigate the present tactics and future prospects of lipid-based nanocarriers in the field of targeted cancer treatment. The goals include the examination of recent progress in the development of lipid nanocarriers, evaluating their effectiveness in clinical uses, and pinpointing opportunities for enhancement and novelty. MATERIAL AND
methodsAn extensive literature analysis was performed, including examining current research on the use of lipid-based nanocarriers in cancer treatment. An analysis was conducted on data pertaining to nanocarrier formulations, targeting mechanisms, treatment results, and clinical trials in order to detect trends and new technologies.
resultsRecent progress in lipid-based nanocarriers, including liposomes, solid lipid nanoparticles, and nanoemulsions, has shown enhanced drug delivery and decreased toxicity. Targeting methods, such as the utilisation of ligand-receptor interactions and stimuli-responsive systems, have significantly improved the precision and effectiveness of therapeutics.
conclusionLipid-based nanocarriers have great potential for advancing targeted cancer treatment in the future. Although there has been significant progress, it is essential to continue developing formulation processes and targeting tactics to overcome existing constraints and improve clinical results. Ongoing cooperation across several fields of study will be crucial in effectively applying these nanotechnologies from the laboratory to practical use in healthcare.
Indexed as
Identifiers
40370243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.